Impact of sarcopenia in lenvatinib treatment for hepatocellular carcinoma; A prospective observational study

Impact of sarcopenia in lenvatinib treatment for hepatocellular carcinoma; A prospective observational study - Impact of sarcopenia in lenvatinib treatment for hepatocellular carcinoma; A prospective observational study

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000033757

Enrollment

100

Registered

2018-08-16

Start date

2018-08-17

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hepatocellular carcinoma

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1)HCC diagnosed by typical findings of radiological findings or histologically proven by biopsy 2)No indications for hepatic surgical resection and radiofrequency ablation 3)Measurable lesion detected 4)Child-Pugh class A 5)Performance status 0-1 6)adequate bone marrow 7)adequate renal function

Exclusion criteria

Exclusion criteria: 1)Child-Pugh class B or C 2)Performance status 2 or more 3)Patients with obvious invasion of the bile duct, or invasion at the main portal vein 4)Patients with 50% or higher liver occupation

Design outcomes

Primary

Measure	Time frame
Progression free survival	—

Secondary

Measure	Time frame
Overall survival Objective response Time to progression Child-Pugh B Adverse event	—

Countries

Japan

Contacts

Public ContactTakeshi Hatanaka

Saiseikai Maebashi Hospital Saiseikai Maebashi Hospital

hatanaka@qk9.so-net.ne.jp027-252-6011

Outcome results